Arcellx (ACLX) Other financing activities (2021 - 2025)

Arcellx (ACLX) recorded quarterly Other financing activities of $38.4 million in Q3 2025, up 192010.0% quarter-over-quarter from $20000.0 in Q4 2021.

Arcellx (ACLX) Other financing activities (2021 - 2025) Analysis & Trends

Arcellx's Other financing activities history runs 2 years deep, the most recent figure standing at $38.4 million for Q3 2025.

In Q3 2025, Other financing activities changed N/A year-over-year to $38.4 million; the TTM figure through Sep 2025 stood at $39.1 million (changed N/A YoY), while the FY2025 annual figure was $38.4 million, changed N/A from the prior year.
Other financing activities was $38.4 million for Q3 2025 at Arcellx, up from $20000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $38.4 million in Q3 2025 to a low of $14000.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Arcellx	6.48 Bn	6.48 Bn	-

Download Data